Rabbit Recombinant Monoclonal CD13 antibody - conjugated to Alexa Fluor® 647.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Broad specificity aminopeptidase which plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. Also involved in the processing of various peptides including peptide hormones, such as angiotensin III and IV, neuropeptides, and chemokines. May also be involved the cleavage of peptides bound to major histocompatibility complex class II molecules of antigen presenting cells. May have a role in angiogenesis and promote cholesterol crystallization. May have a role in amino acid transport by acting as binding partner of amino acid transporter SLC6A19 and regulating its activity (By similarity). (Microbial infection) Acts as a receptor for human coronavirus 229E/HCoV-229E. In case of human coronavirus 229E (HCoV-229E) infection, serves as receptor for HCoV-229E spike glycoprotein. (Microbial infection) Mediates as well Human cytomegalovirus (HCMV) infection.
CD13, APN, PEPN, ANPEP, Aminopeptidase N, AP-N, hAPN, Alanyl aminopeptidase, Aminopeptidase M, Microsomal aminopeptidase, Myeloid plasma membrane glycoprotein CD13, gp150, AP-M
Rabbit Recombinant Monoclonal CD13 antibody - conjugated to Alexa Fluor® 647.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
CD13 also known as aminopeptidase N (ANPEP) is a transmembrane protein with a molecular weight of approximately 150 kDa. It functions as a zinc-dependent metalloenzyme which cleaves N-terminal amino acids from peptides and proteins. CD13 protein is expressed on various cell types including myeloid cells epithelial cells endothelial cells and fibroblasts. Its presence is significantly observed in the brush border of the small intestinal mucosa and the renal proximal tubule. Researchers can study CD13 using anti-CD13 antibodies and CD13 ELISA kits.
CD13 regulates peptide-mediated signaling and controls the maturation and catabolism of bioactive peptides. The enzymatic function of CD13 influences processes such as cell proliferation motility and angiogenesis. It does not operate as part of a larger complex but its activity modulates several cellular and systemic functions. CD13's role in these biological processes highlights its importance in modulating local and systemic peptide pools which contributes to its diverse physiological effects.
CD13 plays significant roles in the renin-angiotensin system and the regulation of inflammatory responses. In the renin-angiotensin system CD13 modulates the activity of angiotensin influencing blood pressure and fluid balance. Through its enzymatic activity CD13 interacts with proteins such as ACE another critical player in this pathway. In inflammation CD13 regulates the availability of chemotactic peptides affecting leukocyte migration and adhesion. The proteins it works with in inflammatory pathways include cytokines which CD13 indirectly modulates by altering chemokine activity.
Aberrant CD13 expression and activity are implicated in cancer and inflammatory diseases. In cancer overexpression of CD13 correlates with tumor growth and metastasis particularly in cancers like renal cell carcinoma and prostate cancer. It can confer an increased malignant phenotype by promoting angiogenesis and immune evasion. In inflammatory disorders dysregulation of CD13 exacerbates diseases such as rheumatoid arthritis through its impact on peptide-mediated signaling and immune cell movement. Its connection with inflammatory cytokines like IL-8 indicates its important role in mediating inflammatory responses.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com